Well, at least I got a response after whining about the silence:



IR CytoDyn <ir@cytodyn.com>
Wed, Oct 18, 8:28 PM (11 hours ago)
to me

Hi ######,



Thank you for your message below. As we recently filed our proxy materials, including our definitive proxy materials on September 25, 2023, we are subject to the SEC’s proxy solicitation rules in responding directly to stockholders and limited in what we can address.



Information on the current status of our plans for developing leronlimab, and related developments that we are able to disclose at this time, is included in our Form 10-K report filed on September 14, 2023. Material information, including updates on key developments, will continue to be conveyed through public filings, press releases or investor calls and will be focused on compliance, accuracy and openness. As we have conveyed in prior messaging, as a matter of both law and principle, we cannot react to external pressures in making announcements or disclosures, but will provide updates as allowed and appropriate. Thank you for your understanding.



Generally speaking, we are – needless to say – focused on and very interested in getting the company back on its feet and seeing through the opportunity that is leronlimab. We anticipate that the next several months will be a critical time period for the company, and hopefully a time in which the clinical hold is removed and we are able to get back to the real mission of our company – developing leronlimab, further exploring the potential ways that leronlimab can be used in treatment, and seeking to increase shareholder value.



We appreciate the spirit in which your message is being sent and are working diligently to drive positive results as soon as possible. This has been a long, and at times frustrating, process over the past year, but we do hope to have positive news to share soon.





Have a nice evening,





CytoDyn Inc. (www.cytodyn.com)

1111 Main Street, Suite 660

Vancouver, Washington 98660

E-mail: cydy_team@cytodyn.com

Office: (360) 980-8524

Facsimile: (360) 799-5954